eFFECTOR Therapeutics, Inc. EFTR
At closeNov 4, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 940
- EPS (ttm)
- -12.78
- Shares out
- 4.70M
- Forward P/E
- -0.02
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 331
- Avg volume
- 1.93K
- Open
- 0.0002
- Previous close
- 0.0002
- Day's range
- 0.0002 – 0.0002
- 52-week range
- 0.0002 – 0.01
- Beta
- 0.62
- Analysts
- Strong Buy
- Price target
- 10.00 (+4999900.0%)
- Earnings date
- Dec 23, 2024
2Y -0.0001 (-33.33%)
Key statistics
- Enterprise value
- -4.95M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -17.67M
- Total cash
- 25.38M
- Total debt
- 20.25M
- Return on equity
- 0.00%
- Short % of float
- 1.97%
- 50-day average
- 0.697539
- 200-day average
- 7.74
Analyst view
Consensus: strong buy
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate -2.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -2.17 | -2.16 | +0.01 | +0.46% |
| Mar 25, 2024 | Dec 1, 2023 | -2.73 | -3.42 | -0.69 | -25.27% |
| Nov 13, 2023 | Sep 1, 2023 | -3.25 | -3.25 | 0.00 | 0.00% |
| Aug 8, 2023 | Jun 1, 2023 | -4.75 | -4.25 | +0.50 | +10.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2023 | HC Wainwright & Co. | init | — | Buy |
| May 25, 2023 | Stifel | up | Hold | Buy |
| May 9, 2023 | Credit Suisse | main | — | Outperform |
| Mar 8, 2023 | Credit Suisse | main | — | Outperform |
| Jan 8, 2023 | JMP Securities | main | — | Market Outperform |
| Jan 5, 2023 | Credit Suisse | main | — | Outperform |
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- effector.com
News
Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS) 
eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast 
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board 
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off 
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq 
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer 
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024 
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update 
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference 
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Your note
Sign in to keep a note on EFTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHATT ELIZABETH | Director | Conversion of Exercise of derivative security | Aug 24, 2021 | 0 |
| BYRNES MICHAEL | Chief Financial Officer | Stock Award(Grant) | May 14, 2024 | 3,117 |
| EHRLICH CHRISTOPHER B | Director | Purchase | Oct 3, 2022 | 178,415 |
| GALLAGHER BRIAN M JR. | Director | Purchase | Jun 22, 2022 | 30,000 |
| PRESIDIO MANAGEMENT GROUP X L L C | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 2, 2022 | 0 |
| ROOT JONATHAN D | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 1, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SR One Capital Management, LP | 11.05% | 6,822,114 | 5.66M | Jun 29, 2023 |
| Carlyle Group Inc. | 7.81% | 4,822,114 | 4.00M | Jun 29, 2023 |
| Column Group LLC | 6.98% | 4,309,329 | 3.58M | Jun 29, 2023 |
| Sectoral Asset Management, Inc. | 3.86% | 2,382,644 | 1.98M | Jun 29, 2023 |
| Parallel Advisors, LLC | 2.74% | 1,693,559 | 1.41M | Jun 29, 2023 |
| Blackstone Inc | 2.12% | 1,308,587 | 1.09M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.49% | 300,033 | 249.09K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.15% | 94,449 | 78.41K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.09% | 55,532 | 51.64K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 24,005 | 22.32K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.02% | 10,545 | 9.81K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.02% | 9,490 | 8.82K | May 30, 2023 |